Orgenesis Inc. Non-operating Income/Expense

Non-operating Income/Expense of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.

Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending September 29, 2021 was $-288 Thousand (a 113.33% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense decreased by -588.14%
  • Annual Non-operating Income/Expense for 2020 was $37 Thousand (a -106.24% decrease from previous year)
  • Annual Non-operating Income/Expense for 2019 was $-593 Thousand (a -122.28% decrease from previous year)
  • Annual Non-operating Income/Expense for 2018 was $2.66 Million (a -185.4% decrease from previous year)
  • Twelve month Non-operating Income/Expense ending September 29, 2021 was $-395 Thousand (a 145.34% increase compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense decreased by -40.24% year-over-year
Trailing Non-operating Income/Expense for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-395 Thousand $-161 Thousand $-363 Thousand $-661 Thousand
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of Orgenesis Inc.

Most recent Non-operating Income/Expenseof ORGS including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of Orgenesis Inc.

Orgenesis Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.29 $-0.14 $-0.03
2020 $0.06 $-0.05 $-0.34 $-0.33 $0.04
2019 $-0.25 $-0.45 $-0.05 $-0.1 $-0.59
2018 $0.02 $-1.27 $0.01 $-2.64 $2.66
2017 $-0.11 $-0.61 $-2.16 $-3.02
2016 $-0.57 $-0.57 $-0.55 $-0.55 $-0.55 $0.1
2015 $1.85
2014 $-0.93
2013 $-0.08
2012 $-0.01
2011 $-0.01

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.